PETRI DISH PERSPECTIVES

25:55

Episode 60: Hims & Hers

PETRI DISH PERSPECTIVES ·

2026/06/18

Send us Fan Mail In this episode of Petri Dish Perspectives, we dive into the rise of Hims & Hers Health, the telehealth company that transformed direct-to-consumer healthcare and challenged traditional medicine. Founded in 2017 by Andrew Dudum, Hims & Hers built a billion-dollar business by removing the stigma around men's and women's health, using digital-first care, subscription medicine, and aggressive branding to reach millions of patients. We explore the company's founding story...

en-us

23:27

Episode 59: Illumina

PETRI DISH PERSPECTIVES ·

2026/06/11

Send us Fan Mail In this episode of Petri Dish Perspectives, we dive into the remarkable story of Illumina, from a small sequencing startup born during the Human Genome Project era to the company that transformed DNA sequencing from a billion-dollar scientific challenge into a routine laboratory tool. We explore how Illumina's sequencing-by-synthesis technology became the gold standard for genomics, enabling everything from cancer research and rare disease diagnosis to population-scale geneti...

en-us

23:59

Episode 58: UnitedHealthcare

PETRI DISH PERSPECTIVES ·

2026/06/04

Send us Fan Mail In this episode of Petri Dish Perspectives, we dive into the remarkable rise of UnitedHealthcare and its parent company, UnitedHealth Group. From its origins in the 1970s managed care movement to becoming a healthcare empire worth hundreds of billions of dollars, UnitedHealthcare has fundamentally transformed how healthcare is financed, delivered, and managed in the United States. We explore the company's founding story, the leadership of industry-defining executives, the cre...

en-us

11:20

May 2026: Biotech & Pharma NEWS Roundup

PETRI DISH PERSPECTIVES ·

2026/06/01

Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for May 2026! This month was dominated by a wave of aggressive cross-border M&A and strategic capital deployment, as pharma giants pivoted to secure the next generation of oncology, metabolic, and infectious disease assets. From high-stakes acquisitions aimed at building comprehensive "acute care" architectures to massive investments in generative AI-driven discovery engines, the industr...

en-us

25:52

Episode 57: 23andMe

PETRI DISH PERSPECTIVES ·

2026/05/28

Send us Fan Mail This week on Petri Dish Perspectives, we unpack the story of 23andMe, the company that turned saliva kits into one of the largest human genetic databases in the world and brought genomics out of hospitals and into millions of homes. From its Silicon Valley origins under Anne Wojcicki to its rise as a consumer genetics pioneer backed by major investors, we explore how 23andMe built a direct-to-consumer model that reshaped public engagement with DNA. We break down the science b...

en-us

23:22

Episode 56: Thermo Fisher

PETRI DISH PERSPECTIVES ·

2026/05/21

Send us Fan Mail This week on Petri Dish Perspectives, we’re diving into the story of Thermo Fisher Scientific, the company quietly powering nearly every corner of modern biotechnology. From its origins in scientific instrumentation to becoming a global life sciences infrastructure giant, we explore how Thermo Fisher built an empire through acquisitions, genomics, diagnostics, contract manufacturing, and the “picks-and-shovels” strategy behind biotech’s biggest breakthroughs. We also unpack t...

en-us

23:36

Episode 55: Alnylam

PETRI DISH PERSPECTIVES ·

2026/05/14

Send us Fan Mail From the discovery of RNA interference to the first FDA-approved gene-silencing therapy, this week on Petri Dish Perspectives, we dive into the story of Alnylam Pharmaceuticals, the company that turned one of biology’s most powerful mechanisms into an entirely new class of medicine. We explore the science behind RNAi, the delivery challenges that nearly killed the field, the leadership of John Maraganore, and how partnerships with Novartis, Sanofi, Regeneron Pharmaceuticals, ...

en-us

16:37

Episode 54: All about 340B

PETRI DISH PERSPECTIVES ·

2026/05/07

Send us Fan Mail In this episode of Petri Dish Perspectives, we break down the 340B Drug Pricing Program, a little-known but massively influential policy shaping how hospitals, pharmacies, and drug manufacturers operate today. Created under the Health Resources and Services Administration, 340B was designed to help safety-net providers stretch scarce resources and serve vulnerable patients. But over time, it has evolved into something much bigger. We unpack how the program actually works, why...

en-us

11:03

April 2026: Biotech & Pharma NEWS Roundup

PETRI DISH PERSPECTIVES ·

2026/05/01

Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for April 2026! This month was dominated by a high-stakes pivot toward oral obesity treatments, a massive consolidation of precision oncology platforms like ADCs and radiopharmaceuticals, and a structural shift toward AI-native drug discovery and in-vivo genomic medicine. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin

en-us

25:01

Episode 53: CAR-T Therapies

PETRI DISH PERSPECTIVES ·

2026/04/30

Send us Fan Mail What if cancer treatment wasn’t a drug but a living, evolving system inside your body? In this episode, we break down one of the most revolutionary innovations in modern medicine: CAR-T cell therapy. From its origins in academic labs to billion-dollar acquisitions by companies like Gilead Sciences, Bristol Myers Squibb, and Novartis, CAR-T represents a fundamental shift, from treating disease to programming the immune system. 🎧 Listen now, stay curious, and don’t forget to

en-us

23:05

Episode 52: Daiichi Sankyo

PETRI DISH PERSPECTIVES ·

2026/04/23

Send us Fan Mail In this episode of Petri Dish Perspectives: Biotech Unleashed, we break down the rise of Daiichi Sankyo, a company that quietly transformed itself from a cardiovascular powerhouse into one of the most dominant players in modern oncology. This isn’t your typical biotech story. There’s no overnight success, no single “eureka” moment. Instead, we trace a century-long evolution, from the pioneering work of Jokichi Takamine and the early days of enzyme therapeutics, to the merger ...

en-us

26:51

Episode 51: ImmunoGen

PETRI DISH PERSPECTIVES ·

2026/04/16

Send us Fan Mail In this episode of Petri Dish Perspectives: Biotech Unleashed, we dive into the 40+ year journey of ImmunoGen, a company that refused to give up on one of the most complex and misunderstood technologies in oncology: antibody-drug conjugates (ADCs). From its early days as a Dana-Farber spinout to decades of scientific setbacks, market skepticism, and near-collapse moments, ImmunoGen’s story is anything but linear. We explore how the company survived the “ADC dark ages,” built ...

en-us

23:34

Episode 50: Exact Sciences

PETRI DISH PERSPECTIVES ·

2026/04/09

Send us Fan Mail In this episode of Petri Dish Perspectives, we’re dissecting the "Phoenix of Biotech." On March 23, 2026, the era of Exact Sciences as an independent company officially ended with its massive $23 billion acquisition by Abbott Laboratories. But the road to this exit wasn't paved with easy wins, it was forged in the wreckage of a "zombie" penny stock that almost didn't survive 2008. We take you through the high-stakes gamble of the DeeP-C trial, the behavioral economics behind ...

en-us

24:43

Episode 49: AI in Pharma / Biotech

PETRI DISH PERSPECTIVES ·

2026/04/02

Send us Fan Mail In this episode, we explore the high-stakes reality of AI integration in the life sciences. We move past the speculative hype to examine the mechanical necessity of this shift, driven by soaring R&D costs and an explosion of biological data, and how the industry has transitioned from a "serendipity-based" model to one of predictive, generative biology. We break down the leaders of this revolution, comparing the "TechBio" pioneers like Insilico and Recursion with the massi...

en-us

13:27

March 2026: Biotech & Pharma NEWS Roundup

PETRI DISH PERSPECTIVES ·

2026/04/01

Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for March 2026! This month was dominated by by three massive themes: more AI integrations, M&A deals, and continued GLP-1 challenges. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

en-us

23:44

Episode 48: Ginkgo Bioworks

PETRI DISH PERSPECTIVES ·

2026/03/26

Send us Fan Mail In this episode of Petri Dish Perspectives, we unpack how Ginkgo Bioworks set out to industrialize biology. From its origins at MIT to building one of the most ambitious synthetic biology platforms in the world, we explore how the company positioned itself not as a traditional biotech, but as a “organism engineering foundry.” We break down Ginkgo’s unique business model, partnering with companies across pharma, agriculture, and consumer goods and how it generates value throug...

en-us

24:12

Episode 47: SUN Pharma

PETRI DISH PERSPECTIVES ·

2026/03/19

Send us Fan Mail From a small operation built on just ₹10,000 to a global pharmaceutical powerhouse, Sun Pharmaceutical Industries is one of the most compelling growth stories in modern biotech. In this episode of Petri Dish Perspectives: Biotech Unleashed, we break down how Dilip Shanghvi transformed a niche generics business into one of the largest pharmaceutical companies in the world. We explore Sun Pharma’s early focus on underserved therapeutic areas, its aggressive strategy of acquirin...

en-us

23:15

Episode 46: Servier

PETRI DISH PERSPECTIVES ·

2026/03/12

Send a text In this episode of Petri Dish Perspectives, we explore the remarkable history of Servier, France’s largest independent pharmaceutical company and one of the only major drugmakers owned by a non-profit foundation. Founded in 1954 by the physician-pharmacist Jacques Servier, the company grew from a tiny laboratory in Orléans into a global powerhouse in cardiovascular and metabolic medicine. For decades, Servier built its reputation developing treatments for hypertension and diabetes...

en-us

23:45

Episode 45: BioMarin

PETRI DISH PERSPECTIVES ·

2026/03/05

Send a text Most biotech companies chase massive markets. But BioMarin Pharmaceutical built its entire strategy around something very different: ultra-rare genetic diseases affecting only small patient populations around the world. In this episode of Petri Dish Perspectives: Biotech Unleashed, we break down how BioMarin became one of the most influential rare-disease biotech companies in the industry. We explore the company’s founding vision, the scientific pathways behind its major therapies...

en-us

10:44

February 2026: Biotech & Pharma NEWS Roundup

PETRI DISH PERSPECTIVES ·

2026/03/01

Send a text Welcome to your essential overview of the global biotech and pharmaceutical landscape for February 2026! This month was dominated by by three massive themes: The Great IPO Thaw, the "AI Factory" Era, and Regulatory Hardball. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 Petri Dish Perspectives LLC. All rights reserved.

en-us

All Episodes

Similar Podcasts

NÖÖRDS - Der Podcast

NÖÖRDS

生命科学の冒険者

あき、とみー

People Who Read People: A Behavior and Psychology Podcast

Zachary Elwood

MEER Media

MEER (Mirrors for Earth"s Energy...

Vintage Sci-Fi Story Anthology

Various